The impact of IPTi and IPTc interventions on malaria clinical burden - in silico perspectives.
BACKGROUND
Clinical management of malaria is a major health issue in sub-Saharan Africa. New strategies based on intermittent preventive treatment (IPT) can tackle disease burden by simultaneously reducing frequency of infections and life-threatening illness in infants (IPTi) and children (IPTc), while allowing for immunity to build up. However, concerns as to whether immunity develops efficiently in treated individuals, and whether there is a rebound effect after treatment is halted, have made it imperative to define the effects that IPTi and IPTc exert on the clinical malaria scenario.


RESULTS
Here, we simulate several schemes of intervention under different transmission settings, while varying immunity build up assumptions. Our model predicts that infection risk and effectiveness of acquisition of clinical immunity under prophylactic effect are associated to intervention impact during treatment and follow-up periods. These effects vary across regions of different endemicity and are highly correlated with the interplay between the timing of interventions in age and the age dependent risk of acquiring an infection. However, even when significant rebound effects are predicted to occur, the overall intervention impact is positive.


CONCLUSIONS
IPTi is predicted to have minimal impact on the acquisition of clinical immunity, since it does not interfere with the occurrence of mild infections, thus failing to reduce the underlying force of infection. On the contrary, IPTc has a significant potential to reduce transmission, specifically in areas where it is already low to moderate.
Aguas
Ricardo
R
Instituto Gulbenkian de Ciência, Oeiras, Portugal. ricaguas@igc.gulbenkian.pt
Lourenço
José M L
JM
Gomes
M Gabriela M
MG
White
Lisa J
LJ
D017954:Africa South of the Sahara / Q000453:epidemiology; D002648:Child; D006801:Humans; D007223:Infant; D008288:Malaria / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control / Q000635:transmission; D008962:Models, Theoretical; D012307:Risk Factors; D012621:Seasons
Lancet. 2005 Apr 23-29;365(9469):1481-3
15850632
Trends Parasitol. 2006 Jul;22(7):296-300
16713739
Bull World Health Organ. 2003;81(3):205-16
12764517
Malar J. 2008 Feb 26;7:37
18302771
Lancet. 2008 Nov 1;372(9649):1555-62
18984188
PLoS Med. 2005 Jan;2(1):e3
15696210
Lancet. 1997 Sep 20;350(9081):844-50
9310602
Malar J. 2007 Jul 06;6:88
17617910
Malar J. 2005 Jul 20;4:33
16033653
Am J Trop Med Hyg. 2004 Jan;70(1):1-7
14971690
Malar J. 2008 Apr 03;7:54
18387180
BMJ. 2005 Oct 1;331(7519):727-33
16195288
Lancet. 2006 Feb 25;367(9511):659-67
16503464
Trop Med Int Health. 2004 Jan;9(1):68-76
14728609
Lancet. 2008 Jul 12;372(9633):127-38
18620950
Bull World Health Organ. 1999;77(8):624-40
10516785
Antimicrob Agents Chemother. 2007 Sep;51(9):3273-81
17638703
Malar J. 2007 Jan 22;6:9
17241476
Am J Trop Med Hyg. 2004 Aug;71(2 Suppl):80-6
15331822
PLoS One. 2008 Jul 16;3(7):e2661
18628828
J Infect Dis. 2005 Jan 1;191(1):109-16
15593011
Am J Trop Med Hyg. 1999 Mar;60(3):410-20
10466970
Nature. 2005 Mar 10;434(7030):214-7
15759000
PLoS One. 2009;4(2):e4383
19198649
Parasite Immunol. 2004 Nov-Dec;26(11-12):477-86
15771683
Trop Med Int Health. 2004 Mar;9(3):351-60
14996364
Lancet. 1997 Jun 7;349(9066):1650-4
9186382
PLoS One. 2008 Mar 12;3(3):e1767
18335042
Trans R Soc Trop Med Hyg. 2004 Feb;98(2):73-81
14964805
Am J Trop Med Hyg. 2007 Aug;77(2):235-41
17690392
Malar J. 2007 Nov 08;6:144
17996048
PLoS Med. 2006 May;3(5):e141
16573365
Malar J. 2008 Jul 08;7:123
18611271
Trop Med Int Health. 1998 Aug;3(8):667-77
9735937
Ann Trop Med Parasitol. 1995 Aug;89(4):359-76
7487223
Lancet. 2005 Aug 27-Sep 2;366(9487):717-25
16125588
PLoS One. 2008 Jan 23;3(1):e1471
18213379
Lancet. 1999 Feb 20;353(9153):632-6
10030329